Brit J Heamatol:同型半胱氨酸与镰状细胞病患者微血管病变的严重程度有关

2020-04-28 MedSci原创 MedSci原创

年龄和同型半胱氨酸浓度是SCD患者微血管病变的独立预测因子。

镰状细胞病(SCD)的病理生理学机制中包括血管病变和贫血。血浆同型半胱氨酸升高是血管疾病的危险因素,可能与SCD患者血管并发症的风险增加有关。

近日,血液系统疾病权威杂志British Journal of Haematology上发表了一篇研究文章,在该研究中,研究人员使用计算机辅助活体显微镜的无创性技术评估了18例小儿和18例成年SCD患者球结膜的微血管特征。研究人员计算了血管病变严重程度指数(SI)以量化每位患者的微血管病变程度,并测量了血浆同型半胱氨酸及其几个决定因素[血清叶酸和维生素B12、血浆磷酸吡哆醛(维生素B6的状态)和肌酐(肾功能)]。

年龄与SCD患者的微血管病变密切相关,年龄每增加1岁,SI升高约0.1个单位(P<0.001)。在调整了年龄、性别、维生素B状态和肌酐后,高半胱氨酸浓度与严重程度指数直接相关(P<0.05)。年龄和同型半胱氨酸浓度是SCD患者微血管病变的独立预测因子。

然而,使用适当的维生素B补充剂(叶酸和维生素B12和B6)降低同型半胱氨酸的浓度是否可以改善SCD患者的微血管病变及其相关并发症,仍有待进一步明确。

原始出处:

Sandra L. Samarron.et al.Homocysteine is associated with severity of microvasculopathy in sickle cell disease patients.british journal of haematology.2020.https://doi.org/10.1111/bjh.16618           

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1006093, encodeId=a48b1006093b6, content=系统性学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc5555760, createdName=ms3000001741732165, createdTime=Sun Aug 08 18:36:14 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644843, encodeId=42421644843a0, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Aug 17 20:49:37 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365403, encodeId=4dcf136540330, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391106, encodeId=34631391106d4, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492052, encodeId=5f12149205202, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615523, encodeId=d248161552371, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2021-08-08 ms3000001741732165

    系统性学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1006093, encodeId=a48b1006093b6, content=系统性学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc5555760, createdName=ms3000001741732165, createdTime=Sun Aug 08 18:36:14 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644843, encodeId=42421644843a0, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Aug 17 20:49:37 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365403, encodeId=4dcf136540330, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391106, encodeId=34631391106d4, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492052, encodeId=5f12149205202, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615523, encodeId=d248161552371, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1006093, encodeId=a48b1006093b6, content=系统性学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc5555760, createdName=ms3000001741732165, createdTime=Sun Aug 08 18:36:14 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644843, encodeId=42421644843a0, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Aug 17 20:49:37 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365403, encodeId=4dcf136540330, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391106, encodeId=34631391106d4, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492052, encodeId=5f12149205202, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615523, encodeId=d248161552371, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2020-04-30 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1006093, encodeId=a48b1006093b6, content=系统性学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc5555760, createdName=ms3000001741732165, createdTime=Sun Aug 08 18:36:14 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644843, encodeId=42421644843a0, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Aug 17 20:49:37 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365403, encodeId=4dcf136540330, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391106, encodeId=34631391106d4, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492052, encodeId=5f12149205202, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615523, encodeId=d248161552371, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1006093, encodeId=a48b1006093b6, content=系统性学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc5555760, createdName=ms3000001741732165, createdTime=Sun Aug 08 18:36:14 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644843, encodeId=42421644843a0, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Aug 17 20:49:37 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365403, encodeId=4dcf136540330, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391106, encodeId=34631391106d4, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492052, encodeId=5f12149205202, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615523, encodeId=d248161552371, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1006093, encodeId=a48b1006093b6, content=系统性学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc5555760, createdName=ms3000001741732165, createdTime=Sun Aug 08 18:36:14 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644843, encodeId=42421644843a0, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Aug 17 20:49:37 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365403, encodeId=4dcf136540330, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391106, encodeId=34631391106d4, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492052, encodeId=5f12149205202, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615523, encodeId=d248161552371, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Thu Apr 30 03:49:37 CST 2020, time=2020-04-30, status=1, ipAttribution=)]

相关资讯

JCEM:孕妇B12、叶酸和同型半胱氨酸的浓度以及子代对应激的皮质醇和心血管反应

该研究的结果表明,孕妇单碳营养素的状况可能对子代的神经内分泌应激反应具有长期的影响。

Eur J Gastroenterol Hepatol:同型半胱氨酸:自发性细菌性腹膜炎中的一种新的诊断标志物

这一研究表明,血清和腹水的同型半胱氨酸在患有SBP的患者中显著升高。血清同型半胱氨酸可能为SBP提供可靠和非侵入性的诊断标记。

Ann Neurol:同型半胱氨酸和小血管卒中

这些发现表明,降低同型半胱氨酸的治疗在预防卒中的作用将局限于SVS亚型。MTHFR和MUT基因或附近的遗传变异是否通过除同型半胱氨酸水平和下游效应之外的途径影响SVS风险需要进一步研究。

J Neurol Neurosur Ps:血清同型半胱氨酸与痴呆风险

血清高tHcy水平与痴呆、AD和VaD风险增高呈非线性关系,仅在tHcy水平相对高的范围内存在剂量-反应相关性。

Nat Commun:张霆/赵世民合作组首次揭示组蛋白同型半胱氨酸修饰在神经管畸形发生中的病理机制

表观遗传异常导致疾病的研究方面,目前主要集中在DNA甲基化以及常见一些组蛋白修饰例如乙酰化、泛素化、甲基化等。然而关于一些少见的组蛋白修饰例如同型半胱氨酸修饰与疾病的发生机理研究相对研究较少。而神经管畸形(Neural tube defects, NTD)是研究这一营养代谢、表观遗传修饰的比较理想的疾病模型。

必须知道:同型半胱氨酸是心脑血管疾病的独立危险因子

H型高血压相信大家不陌生。它是一种有高同型半胱氨酸血症(Hcy)的原发性高血压(>10umol/L)。北京大学第一医院李建平教授等在一项6城市的研究数据显示,我国成年高血压患者中,H型高血压约占75%。